nuclear transport factor 2 pseudogene 8Genealiases: []
Q-omics provides the consensus-scored NUTF2P8 profile across patient tissues and cancer cell-line models. NUTF2P8 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, NUTF2P8 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, NUTF2P8 RNA expression shows 5,751 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight STAD, and CCRCC as cancer lineages where NUTF2P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTF2P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTF2P8 survival associations across molecular data types. NUTF2P8 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTF2P8 RNA expression–survival associations across cancer types. High NUTF2P8 expression shows unfavorable associations in STAD, BRCA, MESO, LGG, GBM and KIRC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify STAD as the clearest survival context for NUTF2P8 RNA expression.
This table summarizes NUTF2P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for NUTF2P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTF2P8 shows lower tumor expression in STAD and higher tumor expression in KIRC. The STAD box plot shows higher NUTF2P8 RNA expression in normal versus tumor tissue (log2 FC = −0.053, t-test p = .010).
This table shows molecular features associated with NUTF2P8 in patient tissues and cancer cell lines. In patient samples, NUTF2P8 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
